JP2013541587A5 - - Google Patents

Download PDF

Info

Publication number
JP2013541587A5
JP2013541587A5 JP2013537807A JP2013537807A JP2013541587A5 JP 2013541587 A5 JP2013541587 A5 JP 2013541587A5 JP 2013537807 A JP2013537807 A JP 2013537807A JP 2013537807 A JP2013537807 A JP 2013537807A JP 2013541587 A5 JP2013541587 A5 JP 2013541587A5
Authority
JP
Japan
Prior art keywords
composition
day
cancer
days
dosing regimen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2013537807A
Other languages
English (en)
Japanese (ja)
Other versions
JP2013541587A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2011/059060 external-priority patent/WO2012061551A1/en
Publication of JP2013541587A publication Critical patent/JP2013541587A/ja
Publication of JP2013541587A5 publication Critical patent/JP2013541587A5/ja
Pending legal-status Critical Current

Links

JP2013537807A 2010-11-05 2011-11-03 Nedd8活性化酵素阻害剤の投与 Pending JP2013541587A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US41047810P 2010-11-05 2010-11-05
US61/410,478 2010-11-05
US201161488240P 2011-05-20 2011-05-20
US61/488,240 2011-05-20
PCT/US2011/059060 WO2012061551A1 (en) 2010-11-05 2011-11-03 Administration of nedd8-activating enzyme inhibitor

Publications (2)

Publication Number Publication Date
JP2013541587A JP2013541587A (ja) 2013-11-14
JP2013541587A5 true JP2013541587A5 (cg-RX-API-DMAC7.html) 2014-12-18

Family

ID=46020229

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2013537807A Pending JP2013541587A (ja) 2010-11-05 2011-11-03 Nedd8活性化酵素阻害剤の投与

Country Status (4)

Country Link
US (2) US20120115892A1 (cg-RX-API-DMAC7.html)
EP (1) EP2635287A4 (cg-RX-API-DMAC7.html)
JP (1) JP2013541587A (cg-RX-API-DMAC7.html)
WO (1) WO2012061551A1 (cg-RX-API-DMAC7.html)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013188881A1 (en) * 2012-06-15 2013-12-19 President And Fellows Of Harvard College Compounds, compositions and methods for treating or preventing neurodegenerative disorders
US9200333B2 (en) 2012-07-25 2015-12-01 Indiana University Research And Technology Corporation Methods for identifying modulators of murine double minute 2
CN105407973A (zh) * 2013-05-14 2016-03-16 米伦纽姆医药公司 Nedd8活化酶抑制剂及化学治疗剂的投与
CN106661031B (zh) * 2014-06-24 2019-07-23 大鹏药品工业株式会社 吡咯并嘧啶化合物或其盐、含有其的药物组合物及应用
TWI623316B (zh) * 2015-12-22 2018-05-11 Taiho Pharmaceutical Co Ltd Antitumor effect enhancer derived from pyrrolopyrimidine compound
CN108210497B (zh) * 2016-12-21 2019-12-20 天津大学 化合物mln4924在制备布尼亚病毒科白蛉病毒属病毒抑制剂的应用
US20220133884A1 (en) * 2019-02-26 2022-05-05 Millennium Pharmaceuticals, Inc. Compounds useful as adjuvants

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HRP20120786T1 (hr) * 2006-02-02 2012-11-30 Millennium Pharmaceuticals, Inc. Inhibitori aktivirajuä†eg enzima e1
EP2540727B1 (en) * 2007-08-02 2018-07-25 Millennium Pharmaceuticals, Inc. Sulfamoylating reagent
WO2009038701A2 (en) * 2007-09-17 2009-03-26 Schering Corporation Formulation containing cyclin-dependent kinase inhibiting compound and method of treating tumors using the same
EP2430026A1 (en) * 2009-05-14 2012-03-21 Millennium Pharmaceuticals, Inc. Hydrochloride salt of ((1s,2s,4r)-4-{4-[(1s)-2,3-dihydro-1h-inden-1-ylamino]-7h-pyrrolo [2,3-d]pyrimidin-7-yl}-2-hydroxycyclopentyl)methyl sulfamate

Similar Documents

Publication Publication Date Title
JP2012515217A5 (cg-RX-API-DMAC7.html)
JP2015532292A5 (cg-RX-API-DMAC7.html)
JP2013067645A5 (cg-RX-API-DMAC7.html)
Falcone et al. Sequence effect of irinotecan and fluorouracil treatment on pharmacokinetics and toxicity in chemotherapy-naive metastatic colorectal cancer patients
FI3757126T3 (fi) Menetelmä nivelreuman hoitamiseksi il-17-antagonistien avulla
JP2016530280A5 (cg-RX-API-DMAC7.html)
JP2011251975A5 (cg-RX-API-DMAC7.html)
JP2010515709A5 (cg-RX-API-DMAC7.html)
Gorlick et al. Testing of the Akt/PKB inhibitor MK‐2206 by the pediatric preclinical testing program
JP2013518086A5 (cg-RX-API-DMAC7.html)
JP2012193216A5 (cg-RX-API-DMAC7.html)
JP2012515184A5 (cg-RX-API-DMAC7.html)
RU2017134443A (ru) Способ лечения с применением традипитанта
PH12014500735A1 (en) Blood coagulation factor vii and viia derivatives, conjugates and complexes comprising the same, and use thereof
JP2012180381A5 (cg-RX-API-DMAC7.html)
JP2013541583A5 (cg-RX-API-DMAC7.html)
Wang et al. The bone, the joints and the Balm of Gilead
CY1118158T1 (el) Δευτεριωμενα 1-πιπεραζινο-3-φαινυλικα ινδανια για τη θεραπευτικη αντιμετωπιση της σχιζοφρενιας
JP2017537927A5 (cg-RX-API-DMAC7.html)
EP4424709A3 (en) Dosing regimen for anti-bcma agents
JP2010525042A5 (cg-RX-API-DMAC7.html)
CN114259566B (zh) 一种基于破坏氧化还原平衡的抗肿瘤组合物及应用
JP2013540734A5 (cg-RX-API-DMAC7.html)
JP2014510780A5 (cg-RX-API-DMAC7.html)
JP2006503095A5 (cg-RX-API-DMAC7.html)